We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+13.19%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$12.1B
AUM Growth
+$1.25B
Cap. Flow
-$1.53B
Cap. Flow %
-12.71%
Top 10 Hldgs %
75.84%
Holding
141
New
6
Increased
25
Reduced
5
Closed
8

Top Buys

Rank Stock Value
1
ACOR
Acorda Therapeutics
ACOR
+$90.4M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$52.6M
3
DYAX
DYAX CORPORATION
DYAX
+$24.1M
4
ALKS icon
Alkermes
ALKS
+$17.5M
5
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$15.8M

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$18.6M
2
XNPT
XENOPORT, INC.
XNPT
+$17M
3
ALDR
Alder Biopharmaceuticals
ALDR
+$16.8M
4
RPRX
Repros Therapeutics Inc.
RPRX
+$14.5M
5
LRMR icon
Larimar Therapeutics
LRMR
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 73.26%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDVN
26
DELISTED
MEDIVATION, INC.
MDVN
$31.9M 0.26%
659,752
– –
PGNX
27
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$26.7M 0.22%
4,350,808
– –
GILD icon
28
Gilead Sciences
GILD
$166B
$25.3M 0.21%
249,995
– –
TGTX icon
29
TG Therapeutics
TGTX
$8.17B
$23.9M 0.2%
2,003,991
– –
LKFT
30
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$23.2M 0.19%
369,276
– –
ATYR
31
aTyr Pharma
ATYR
$47.1M
$23M 0.19%
166,795
– –
ACHN
32
DELISTED
Achillion Pharmaceuticals
ACHN
$21.6M 0.18%
2,000,000
– –
ACGN
33
DELISTED
Aceragen Inc
ACGN
$21.6M 0.18%
51,398
+51
+0.1% +$22.8K
CPRX
34
DELISTED
Catalyst Pharmaceutical
CPRX
$20.3M 0.17%
8,275,630
+939,938
+13% +$2.69M
ALKS icon
35
Alkermes
ALKS
$8.08B
$19.9M 0.16%
+250,251
New +$17.5M
XNPT
36
DELISTED
XENOPORT, INC.
XNPT
$19.1M 0.16%
3,475,672
-3,032,950
-47% -$17M
NVAX icon
37
Novavax
NVAX
$1.21B
$18.4M 0.15%
109,784
– –
ARRY
38
DELISTED
Array Biopharma Inc
ARRY
$18.2M 0.15%
4,310,666
– –
INSM icon
39
Insmed
INSM
$22.6B
$18.1M 0.15%
1,000,000
-583,490
-37% -$10.3M
AAAP
40
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$17.7M 0.15%
+567,454
New +$15.8M
DSCI
41
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$17.1M 0.14%
3,752,390
+294,549
+9% +$1.4M
FOMX
42
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$16.6M 0.14%
2,046,967
– –
ZGNX
43
DELISTED
Zogenix, Inc.
ZGNX
$14.7M 0.12%
1,000,000
-798,365
-44% -$10.7M
ARCT icon
44
Arcturus Therapeutics
ARCT
$160M
$14.7M 0.12%
333,766
+99,499
+42% +$4.48M
IOVA icon
45
Iovance Biotherapeutics
IOVA
$2.03B
$14M 0.12%
1,817,429
– –
DMTX
46
DELISTED
Dimension Therapeutics, Inc
DMTX
$13.9M 0.12%
+1,234,481
New +$15.6M
RARE icon
47
Ultragenyx Pharmaceutical
RARE
$2.49B
$13.9M 0.12%
123,894
– –
GBT
48
DELISTED
Global Blood Therapeutics, Inc.
GBT
$12.9M 0.11%
400,000
+200,000
+100% +$8.66M
XNCR icon
49
Xencor
XNCR
$1.46B
$12.8M 0.11%
872,072
– –
MGNX icon
50
MacroGenics
MGNX
$235M
$11.3M 0.09%
363,676
+15,900
+5% +$483K
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2015 Portfolio in Review

As of Q4 2015, Baker Bros. Advisors held 141 positions worth $12.1B, up 12% from $10.8B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Baker Bros. Advisors withdrew a net $1.53B in Q4 2015, closing 8 positions and reducing 5 holdings. Its most notable exit was Clovis Oncology, Inc., an estimated $18.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 74% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in Alkermes worth $19.9M.

  • Baker Bros. Advisors's largest Q4 2015 buy was Alkermes: 250,251 shares worth $19.9M.
  • Baker Bros. Advisors added most to Acorda Therapeutics in Q4 2015, an estimated $90.4M increase.
  • Baker Bros. Advisors's biggest Q4 2015 reduction was XENOPORT, INC., cutting an estimated $17M.
  • Baker Bros. Advisors fully exited Clovis Oncology, Inc. in Q4 2015, selling an estimated $18.6M.
  • Baker Bros. Advisors's ten largest holdings make up 76% of its $12.1B portfolio in Q4 2015.
  • Baker Bros. Advisors opened 6 new positions and closed 8 in Q4 2015.
  • Baker Bros. Advisors's portfolio value rose 12% quarter-over-quarter to $12.1B.

Based on Baker Bros. Advisors's 13F filing for Q4 2015, filed 16 Feb 2016.